New Glaucoma Treatment Effective in Trial

Wednesday, 25 Jun 2014 12:15 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Drug developer Aerie Pharmaceuticals Inc said its single-drop eye treatment was shown to be superior to each of its two components in a mid-stage trial, sending its shares up by about 24 percent in premarket trading.
The drug, Roclatan, combines Aerie's other experimental glaucoma drug Rhopressa with the approved latanoprost.
Patients treated with the drug experienced a significant reduction in fluid pressure inside the eye, compared with those treated with either latanoprost or Rhopressa.
Glaucoma is a condition in which increased eye pressure could damage the optic nerve and lead to blindness, if left untreated.
Aerie Pharma said it would immediately start preparing for Roclatan's late-stage trial.
It is also preparing to start a late-stage trial for Rhopressa early in the third quarter.
 

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Low-Carb Diet Beats Low-Fat for Weight Loss: Study

Monday, 01 Sep 2014 21:26 PM

Alow-carbohydrate diet is better for losing weight and may also be better for lowering the risk of heart disease than a  . . .

Eating Pistachios Can Prevent Diabetes: Study

Monday, 01 Sep 2014 13:04 PM

For people who may be headed for Type 2 diabetes, regularly eating pistachios might help turn the tide, according to a n . . .

Medicare May Cover End-of-Life 'Death Panel' Talks

Monday, 01 Sep 2014 10:56 AM

Five years after the political firestorm over 'death panels,' the issue of paying doctors to talk to patients about end- . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved